The genetic risk of gestational diabetes in South Asian women
- McMaster University, Canada
- Bradford Royal Infirmary, United Kingdom
- University of Bristol, United Kingdom
Abstract
South Asian women are at increased risk of developing gestational diabetes (GDM). Few studies have investigated the genetic contributions to GDM risk. We investigated the association of a type 2 diabetes (T2D) polygenic risk score (PRS), on its own, and with GDM risk factors, on GDM-related traits using data from two birth cohorts in which South Asian women were enrolled during pregnancy. 837 and 4,372 pregnant South Asian women from the SouTh Asian BiRth CohorT (START) and Born in Bradford (BiB) cohort studies underwent a 75-gram glucose tolerance test. PRSs were derived using GWAS results from an independent multi-ethnic study (~18% South Asians). Associations with fasting plasma glucose (FPG); 2h post-load glucose (2hG); area under the curve glucose; and GDM were tested using linear and logistic regressions. The population attributable fraction (PAF) of the PRS was calculated. Every 1 SD increase in the PRS was associated with a 0.085 mmol/L increase in FPG ([95%CI=0.07-0.10], P=2.85 × 10-20); 0.21 mmol/L increase in 2hG ([95%CI=0.16-0.26], P=5.49 × 10-16); and a 45% increase in the risk of GDM ([95%CI=32-60%], P=2.27 × 10-14), independent of parental history of diabetes and other GDM risk factors. PRS tertile 3 accounted for 12.5% of the population's GDM alone, and 21.7% when combined with family history. A few weak PRS and GDM risk factors interactions modulating FPG and GDM were observed. Together, these results show that a T2D PRS and family history of diabetes are strongly and independently associated with multiple GDM-related traits in women of South Asian descent, an effect that could be modulated by other environmental factors.
Data availability
Data from START is not publicly available, since the study is bound by consent which indicates the data will not be used by an outside group. Requests for collaboration or replication will be considered for research purposes only (no commercial use allowed, as per the study's informed consent). Requests should be addressed to the study's principal investigator (Sonia Anand, anands@mcmaster.ca) via a form which will be provided upon request by emailing natcampb@mcmaster.ca. The request will be evaluated by PIs and co-investigators, and projects deemed of scientific interest will be further evaluated/validated by local REB chair. Born in Bradford data are available for research purposes only by sending an expression of interest form downloadable from https://borninbradford.nhs.uk/wp-content/uploads/BiB_EoI_v3.1_10.05.21.doct to borninbradford@bthft.nhs.uk . The proposal will be reviewed by BiB's executive team. If the request is approved, the requester will be asked to sign a Data Sharing Contract and a Data Sharing Agreement. Full details on how to access data and forms can be found here https://borninbradford.nhs.uk/research/how-to-access-data/. The code used to analyze the data is available at https://github.com/AmelLamri/Paper_T2dPrsGdm_StartBiB. All Sharable processed versions of the datasets used in the manuscript are made available as supplementary material or at https://github.com/AmelLamri/Paper_T2dPrsGdm_StartBiB.
Article and author information
Author details
Funding
Canadian Institutes of Health Research (Project grant 298104;Foundation grant number: FDN-143255)
- Sonia S Anand
Bristol NIHR Biomedical Research Center
- Deborah A Lawlor
UK Medical Research Council (MC_UU_00011/6)
- Deborah A Lawlor
British Heart Foundation (CH/F/20/90003)
- Deborah A Lawlor
Canada Research Chairs
- Sonia S Anand
Heart and Stroke Foundation/Michael G. DeGroote Chair
- Sonia S Anand
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Human subjects: All START and BiB participants provided informed consent. The START study was approved by local ethics committees (Hamilton Integrated Research Ethics Board [ID:10-640], William Osler Health System [ID:11-0001], and Trillium Health Partners [RCC:11-018, ID:492]). Ethical approval for all aspects of the research was granted by Bradford Research Ethics Committee [Ref 07/H1302/112].
Copyright
© 2022, Lamri et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,818
- views
-
- 140
- downloads
-
- 17
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
The genetic risk of gestational diabetes in South Asian women
eLife 11:e81498.
https://doi.org/10.7554/eLife.81498
Further reading
-
- Genetics and Genomics
Resistance to anthelmintics, particularly the macrocyclic lactone ivermectin (IVM), presents a substantial global challenge for parasite control. We found that the functional loss of an evolutionarily conserved E3 ubiquitin ligase, UBR-1, leads to IVM resistance in Caenorhabditis elegans. Multiple IVM-inhibiting activities, including viability, body size, pharyngeal pumping, and locomotion, were significantly ameliorated in various ubr-1 mutants. Interestingly, exogenous application of glutamate induces IVM resistance in wild-type animals. The sensitivity of all IVM-affected phenotypes of ubr-1 is restored by eliminating proteins associated with glutamate metabolism or signaling: GOT-1, a transaminase that converts aspartate to glutamate, and EAT-4, a vesicular glutamate transporter. We demonstrated that IVM-targeted GluCls (glutamate-gated chloride channels) are downregulated and that the IVM-mediated inhibition of serotonin-activated pharynx Ca2+ activity is diminished in ubr-1. Additionally, enhancing glutamate uptake in ubr-1 mutants through ceftriaxone completely restored their IVM sensitivity. Therefore, UBR-1 deficiency-mediated aberrant glutamate signaling leads to ivermectin resistance in C. elegans.
-
- Genetics and Genomics
Osteoporosis, characterized by reduced bone density and strength, increases fracture risk, pain, and limits mobility. Established therapies of parathyroid hormone (PTH) analogs effectively promote bone formation and reduce fractures in severe osteoporosis, but their use is limited by potential adverse effects. In the pursuit of safer osteoporosis treatments, we investigated R25CPTH, a PTH variant wherein the native arginine at position 25 is substituted by cysteine. These studies were prompted by our finding of high bone mineral density in a hypoparathyroidism patient with the R25C homozygous mutation, and we explored its effects on PTH type-1 receptor (PTH1R) signaling in cells and bone metabolism in mice. Our findings indicate that R25CPTH(1–84) forms dimers both intracellularly and extracellularly, and the synthetic dimeric peptide, R25CPTH(1–34), exhibits altered activity in PTH1R-mediated cyclic AMP (cAMP) response. Upon a single injection in mice, dimeric R25CPTH(1–34) induced acute calcemic and phosphaturic responses comparable to PTH(1–34). Furthermore, repeated daily injections increased calvarial bone thickness in intact mice and improved trabecular and cortical bone parameters in ovariectomized (OVX) mice, akin to PTH(1–34). The overall results reveal a capacity of a dimeric PTH peptide ligand to activate the PTH1R in vitro and in vivo as PTH, suggesting a potential path of therapeutic PTH analog development.
